VAXIMM AG

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

VAXIMM to Attend International Scientific and Industry Events

VAXIMM Announces Participation at Scientific and Industry Events in May

VAXIMM to Participate at Upcoming Scientific and Industry Events

VAXIMM Appoints Thomas D. Szucs, MD, as Chairman of the Board

VAXIMM Announces First Results from Phase I/II Trial in Progressive Glioblastoma with Oral T-cell Immunotherapy VXM01 in Combination with PD-L1 Inhibitor Avelumab to be Presented at ASCO20 Virtual

VAXIMM to Participate at Upcoming Industry Events

NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines

VAXIMM Announces Presentations at ASCO 2019 and Other Upcoming Industry and Scientific Events

VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma

VAXIMM Announces Presentations at Upcoming Industry and Scientific Events

VAXIMM Announces Regional Development and Commercialization Agreement with China Medical System Holdings

VAXIMM Announces Final Results from Phase I Trial in Recurrent Glioblastoma with Oral T-cell Immunotherapy VXM01 to be Presented at 2018 ASCO Annual Meeting

VAXIMM Announces Presentations at Upcoming Industry and Scientific Events

VAXIMM Announces Presentations at Upcoming Industry and Scientific Events

VAXIMM Announces Preclinical Results with Novel Oral T cell Cancer Immunotherapies Being Presented at AACR-NCI-EORTC International Conference

VAXIMM Receives Orphan Designation for the European Union and the US for Oral T-cell Immunotherapy VXM01 to Treat Glioma

VAXIMM Announces Preclinical Results with Novel Oral T-cell Cancer Immunotherapies Being Presented at Third CRI-CIMT-EATI-AACR Conference

VAXIMM Announces Data from Phase I Trial in Glioblastoma with Oral T-cell Immunotherapy VXM01 to be Presented at ASCO 2017 Annual Meeting

VAXIMM Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of VXM01 with Avelumab in Glioblastoma and Colorectal Cancer in Phase I/II Clinical Studies

VAXIMM Announces Presentations at Upcoming Industry and Scientific Events

VAXIMM to present preclinical data on three novel oral T-cell immunotherapies at AACR Annual Meeting 2017

VAXIMM Announces Presentation at Biotech Showcase in San Francisco

VAXIMM Presents Preclinical Data on Three Novel Oral T-Cell Cancer Immunotherapies at EORTC-NCI-AACR Symposium

VAXIMM Announces Presentations at Upcoming Industry and Scientific Events

VAXIMM Appoints Dr. Matthias Schroff as Chief Executive Officer

VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01

VAXIMM Elects New Members to Board of Directors

VAXIMM Presents Data from Phase I Trial in Pancreatic Cancer with Oral T-cell Immunotherapy VXM01 at ASCO 2016 Annual Meeting

VAXIMM Announces Data from Phase I Trial in Pancreatic Cancer with Oral T-cell Immunotherapy VXM01 to be Presented at ASCO 2016 Annual Meeting